FDA Approves Merck’s KEYTRUDA for Patients With MSI‑H/dMMR Advanced Endometrial Carcinoma
Merck, known as MSD outside the US and Canada, announced today that the US Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for…
Read More...
Read More...